BSD Medical Corp. announced May 22 its Pre-market Approval Application (PMAA) for the BSD-2000 cancer treatment system has been accepted for filing and review by the U.S. Food and Drug Administration (FDA). Acceptance for filing indicates that the FDA considers the PMAA (consisting of 7,243 pages contained in 24 volumes) to be complete and warrants full review of the data needed to assess the safety and efficacy of the BSD-2000. FDA acceptance for filing of the PMAA is an important step in the approval process in the United States, but acceptance for filing by the FDA does not mean that the PMAA has been or will be approved. Acceptance of the PMAA for filing by the FDA marks an important milestone for the company. BSD Medical (http://www.bsdmc.com/press.html?id=183)
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Health Canada Opens Consultation on ‘Pause the Clock’ Proposal
The agency would be able to pause the clock for medical device applications linked together that have different review times.
FDA Approves First Immuno-Oncology Drug for Certain Patients Previously Treated for Lung Cancer
The agency said continuing approval for Opdivo may depend on the drug showing clinical benefit in future clinical trials.